Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients

Author:

Mahmoud Tarek12ORCID,Yagan Jude12ORCID,Hasan Amal3ORCID,Gheith Osama A2ORCID,Mostafa Mohamed2,Rida Suzann2,El‐Serwi Nabil2,Shaker Mohamad2,Khalid Mahmoud2

Affiliation:

1. Nephrology Department Jaber Al Ahmed Armed Forces Hospital Subhan Kuwait

2. Nephrology Department Hamed Al‐Essa Organ Transplant Center Sabah Medical Region Kuwait City Kuwait

3. Department of Translational Research Dasman Diabetes Institute Dasman Kuwait

Abstract

AbstractIntroductionCardiovascular and renal complications define the outcomes of diabetic kidney transplant recipients (KTRs). The new diabetes medications have changed the management of diabetes. However, transplant physicians are still reluctant to use sodium–glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) post kidney transplantation due to fear of drug related complications and lack of established guidelines.Patients and methodsWe collected 1‐year follow‐up data from records of 98 diabetic KTRs on SGLT2I, 41 on GLP‐ 1RA and 70 on standard‐of‐care medicines. Patients were more than 3 months post‐transplant with a minimum estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2. Demographic data were similar except for a slightly lower HbA1c in the control group and higher albuminuria in SGLT2i group.ResultsHbA1c dropped significantly by .4% in both SGLT2i and GLP‐1RA compared to .05% in the control group. A significant decrease in BMI by .32 in SGLT2i and .34 in GLP‐1RA was observed compared to an increase by .015 in control group. A tendency for better eGFR in study groups was observed but was non‐significant except for the SGLT2i group with an eGFR above 90 (p = .0135). The usual dip in eGFR was observed in the SGLT2i group at 1–3 months. Albuminuria was significantly reduced in both study groups. Adverse events were minimal with comparable safety in all groups.ConclusionThe use of SGLT2i and GLP‐1RA appears to be effective and safe in diabetic KTRs with good outcomes. Randomized control trials are required to confirm these findings and establish guidelines.

Publisher

Wiley

Subject

Transplantation

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3